Saturday, 20 Sep 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • House
  • VIDEO
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > What You Need to Know Ahead of DexCom’s Earnings Release
Economy

What You Need to Know Ahead of DexCom’s Earnings Release

Last updated: July 7, 2025 7:31 pm
Share
What You Need to Know Ahead of DexCom’s Earnings Release
SHARE

DexCom, Inc. (DXCM), a leading medical device company based in San Diego, specializes in continuous glucose monitoring (CGM) systems. With a market capitalization of $32.5 billion, DexCom’s innovative technology includes a small, implantable sensor that tracks glucose levels beneath the skin and transmits real-time data to an external receiver.

The company is set to announce its fiscal 2025 second-quarter earnings after the market closes on Wednesday, July 30. Analysts are anticipating a profit of $0.45 per share on a diluted basis, reflecting a 4.7% increase from the year-ago quarter’s $0.43 per share. While DexCom has exceeded consensus estimates in two of the last four quarters, it has fallen short on two other occasions.

Looking ahead, analysts project that DXCM will report earnings per share (EPS) of $2.03 for the full year, marking a 23.8% increase from $1.64 in fiscal 2024. Furthermore, the company’s EPS is expected to rise by 24.6% year over year to $2.53 in fiscal 2026.

Over the past 52 weeks, DexCom’s shares have declined by 25.2%, underperforming the S&P 500’s 13.4% gains and the Health Care Select Sector SPDR Fund’s 5.4% dip during the same period. On July 1, the company’s shares experienced a more than 4% drop following the U.S. government’s proposed changes to payment schedules and the introduction of a competitive bidding program for diabetes devices, impacting the broader glucose monitoring and insulin pump sector.

Despite these challenges, analysts maintain a very positive outlook on DXCM stock, with an overall “Strong Buy” rating. Out of 25 analysts covering the stock, 20 recommend a “Strong Buy,” one suggests a “Moderate Buy,” and four advise a “Hold.” The average analyst price target for DXCM is $99.68, indicating a potential upside of 20.2% from the current levels.

See also  Microsoft is key holdout for OpenAI restructuring plan

In conclusion, DexCom continues to innovate in the field of continuous glucose monitoring, despite recent market fluctuations. Investors and analysts remain optimistic about the company’s future prospects, highlighting its strong performance and potential for growth in the coming years.

This article was originally published on Barchart.com and has been rewritten for a WordPress platform, incorporating key points and information from the original source.

TAGGED:aheadDexcomsEarningsRelease
Share This Article
Twitter Email Copy Link Print
Previous Article Conozca sus derechos como inmigrante antes, durante y después de un desastre Conozca sus derechos como inmigrante antes, durante y después de un desastre
Next Article Roger Waters faces possible prosecution after supporting banned Palestine Action Roger Waters faces possible prosecution after supporting banned Palestine Action
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Trump’s Cuts Threaten NASA Plans for Astronauts on Mars

US President Donald Trump recently set a monumental challenge for NASA by directing the agency…

June 7, 2025

Body found in Barker Meadow Reservoir in Boulder County

A Man's Body Found in Barker Meadow Reservoir On Sunday afternoon, a man's body was…

July 6, 2025

Extending the Modification of the Reciprocal Tariff Rates – The White House

In exercising the powers vested in me as President under the Constitution and various U.S.…

July 7, 2025

AI is growing faster than companies can secure it, warn industry leaders

The DataGrail Summit 2024 brought together industry leaders to discuss the rapidly advancing risks associated…

August 31, 2024

The Princess Diaries Cast’s Quotes About Making a 3rd Movie

After the success of two beloved Princess Diaries films, fans have been eagerly awaiting news…

December 14, 2024

You Might Also Like

Is Synchrony Financial Stock Outperforming the Dow?
Economy

Is Synchrony Financial Stock Outperforming the Dow?

September 20, 2025
Wall Street bets on AI chip boom keep getting more concentrated
Economy

Wall Street bets on AI chip boom keep getting more concentrated

September 20, 2025
Evaluating We Have Never Been Woke, Part 1: Elite Overproduction
Economy

Evaluating We Have Never Been Woke, Part 1: Elite Overproduction

September 19, 2025
Stocks finish week higher; Wall Street at record highs
Economy

Stocks finish week higher; Wall Street at record highs

September 19, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?